Valuation: SELLAS Life Sciences Group, Inc.

Market Cap 2.59B 2.27B 2.09B 1.94B 3.69B 247B 3.74B 25.04B 9.75B 121B 9.74B 9.53B 421B P/E 2026 *
-66.4x
P/E 2027 * -92.9x
Enterprise Value 2.59B 2.27B 2.09B 1.94B 3.69B 247B 3.74B 25.04B 9.75B 121B 9.74B 9.53B 421B EV / Sales 2026 *
-
EV / Sales 2027 * 58.6x
Free-Float
99.05%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SELLAS Life Sciences Group, Inc.

1 day-5.77%
1 week-11.18%
Current month-11.18%
1 month+64.29%
3 months+190.69%
6 months+224.50%
Current year+247.75%
1 week 12.75
Extreme 12.75
15.57
1 month 7.07
Extreme 7.07
15.88
Current year 3.23
Extreme 3.23
15.88
1 year 1.39
Extreme 1.39
15.88
3 years 0.5
Extreme 0.4986
15.88
5 years 0.5
Extreme 0.4986
15.88
10 years 0.5
Extreme 0.4986
554.5
Manager TitleAgeSince
Chief Executive Officer 50 2017-12-28
Director of Finance/CFO 41 2017-12-29
Compliance Officer - -
Director TitleAgeSince
Director/Board Member 50 2017-12-28
Chairman 66 2024-05-31
Director/Board Member 69 2017-12-28
Date Insider Type Main position Quantity % Market Cap.
06-15Free

Founder

1,065,000 0.5725%
01-06Free

Director

50,000 0.0351%
01-06Free

Director

50,000 0.0351%
Change 5-day change 1-year change 3-year change Capi.($)
-5.52%-11.18%+504.15%+699.39% 2.59B
-0.10%+0.10%+74.33%+133.26% 57.73B
-3.80%-6.24%+67.04%+86.36% 54.69B
+0.10%+0.67%-14.88%-12.34% 23.75B
+1.34%+5.92%+16.48%+468.63% 24.18B
-2.70%+4.25%+40.38%-3.72% 19.82B
+3.78%+5.65%+44.99%-26.23% 17.14B
+3.46%+17.72%+206.66%+364.07% 16.75B
-1.81%+18.00%+41.99% - 15.57B
+3.08%+5.17%+29.59%+196.35% 13.96B
Average -0.24%+4.03%+101.07%+211.75% 24.62B
Weighted average by Cap. -0.44%+3.20%+62.60%+145.63%

Financials

2026 *2027 *
Net sales - 44.24M 38.75M 35.69M 33.13M 62.91M 4.22B 63.76M 427M 166M 2.07B 166M 163M 7.18B
Net income -37.97M -33.26M -30.63M -28.43M -53.99M -3.62B -54.73M -367M -143M -1.78B -143M -139M -6.16B -29.83M -26.12M -24.06M -22.33M -42.41M -2.85B -42.98M -288M -112M -1.4B -112M -110M -4.84B
Net Debt - -
Logo SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Employees
13
Date Price Change Volume
26-07-07 US$13.14 -5.77% 4,145,347
26-07-06 US$13.94 -6.94% 9,746,734
26-07-02 US$14.98 +12.89% 17,275,558
26-07-01 US$13.27 -10.09% 12,270,549
26-06-30 US$14.76 -4.47% 21,628,763
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
13.94USD
Average target price
17.50USD
Spread / Average Target
+25.54%

Quarterly revenue - Rate of surprise